Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%

Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hyKNisU
via IFTTT

Read More

Experts say health technology, preventive healthcare at inflection point, India ready to leverage

With a focus on preventive healthcare and wellness, India is on the verge of harnessing new technological innovations. Sangita Reddy from Apollo Hospitals stresses the significance of wearable devices in spotting health issues early on. In collaboration with Apollo Hospitals, Garmin Health is targeting rural health efforts and highlighting the event's health technology strides.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1BwDgi8
via IFTTT

Read More

India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs

Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ztCd01h
via IFTTT

Read More

India's first public sector proton beam therapy unit to come up in Assam; state signs MoU with Belgian firm

Assam has signed an MoU with Belgium-based Ion Beam Applications (IBA) to set up India's first public-sector proton beam therapy centre in Guwahati at a cost of Rs 600 crore. The facility will offer advanced cancer treatment, particularly for children, and is expected to take at least three years to become operational.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8QGNRKm
via IFTTT

Read More

Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lV5JvIn
via IFTTT

Read More

Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%

Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lVIyPuW
via IFTTT

Read More

Omron Healthcare eyes Chennai as global manufacturing hub, targets 3 million BP monitors by 2028

Omron Healthcare has commenced full-scale production at its new facility near Chennai for blood pressure monitors. The company aims to produce three million monitors annually by 2028 for the Indian market. Initially, all produced devices will serve local consumers to address cardiovascular health challenges. Omron is also working towards increasing domestic sourcing of components to support local manufacturing initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2JSVslj
via IFTTT

Read More